<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="83028">
  <stage>Registered</stage>
  <submitdate>3/08/2008</submitdate>
  <approvaldate>21/11/2008</approvaldate>
  <actrnumber>ACTRN12608000591358</actrnumber>
  <trial_identification>
    <studytitle>Comparison of two concentrations of local anaesthetic for pain relief after shoulder rotator cuff repair</studytitle>
    <scientifictitle>A comparison of 0.2 and 0.4% Ropivacaine for Ambulatory Patient Controlled Interscalene Analgesia after Rotator Cuff Repair</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Nil Known</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Pain relief after shoulder rotator cuff repair</healthcondition>
    <conditioncode>
      <conditioncode1>Anaesthesiology</conditioncode1>
      <conditioncode2>Other anaesthesiology</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>0.4% ropivacaine for continuous interscalene block after rotator cuff repair for 48 hours postoperatively as required by the patient.</interventions>
    <comparator>0.2% ropivacaine for continuous interscalene block after rotator cuff repair for 48 hours postoperatively as required by the patient.</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Reduced pain after rotator cuff repair, assessed by patient interrogation regarding analgesic consumption and pain scores using numerical rating pain score (NRPS).</outcome>
      <timepoint>1-2 days post operatively.
Analgesic requirements and pain scores (0-10) measured in the afternoon of Day 1 and Day 2 following surgery.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Arm numbness/weakness</outcome>
      <timepoint>First 48 postoperative hours</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Patients requiring continuous interscalene analgesia following rotator cuff repair under the care of the two investigators.</inclusivecriteria>
    <inclusiveminage>0</inclusiveminage>
    <inclusiveminagetype>No limit</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Patient refusal/inability to consent, age no limits
2. Allergy amide local anaesthetic (LA) drugs
3. Existing neurological disorders/neuropathy of the operative extremity
4. Infection at site of needle puncture
5. Severe respiratory disease
6. Chronic opioid therapy
7. Intolerance of all non-steroidal anti-inflammatory drugs (NSAIDs).</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>A dedicated research assistant (Margaret Watkin) will invite patients to be included in the study and will perform the post operative phone call on days 1,2 and 10. The principal investigator will place all interscalene catheters. The patients PACU nurse will be asked to record the patients pain score on arrival in the PACU. Patients will be asked simple questions on postoperative day 1 through 2. Margaret Watkin will also coordinate the 3 month questionnaire.  Assignment of patient to 0.2% or 0.4% concentration of ropivacaine will be delivered in a sealed opaque envelope.</concealment>
    <sequence>A computerised random number generator will be used to assign the patient to one of the 2 groups.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>15/08/2008</anticipatedstartdate>
    <actualstartdate>15/10/2008</actualstartdate>
    <anticipatedenddate />
    <actualenddate>1/04/2009</actualenddate>
    <samplesize>60</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Dr Michael Fredrickson</primarysponsorname>
    <primarysponsoraddress>Anaesthesia Institute
P O Box 109 199
Newmarket
Auckland 1149</primarysponsoraddress>
    <primarysponsorcountry>New Zealand</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>Accident Compensation Corporation (ACC)</fundingname>
      <fundingaddress>P O Box 242
Wellington 6140</fundingaddress>
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>If the primary hypothesis is confirmed, this study will provide evidence supporting the use of a higher concentration of ropivacaine than that which is routinely used in Auckland. At present the community standard is ropivacaine 0.2% for this technique. This may result in future patients experiencing less postoperative pain after rotator cuff repair. Potential benefits might include a lower incidence of post rotator cuff repair chronic pain.</summary>
    <trialwebsite />
    <publication>N/A</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Northern X Regional Ethics Committee</ethicname>
      <ethicaddress>Private Bag 92 522
Wellesley Street
Auckland 1141</ethicaddress>
      <ethicapprovaldate>15/04/2008</ethicapprovaldate>
      <hrec>NTX/08/04/026</hrec>
      <ethicsubmitdate />
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Dr Michael Fredrickson</name>
      <address>Anaesthesia Institute
P O Box 109 199
Newmarket
Auckland 1149</address>
      <phone>+64 9 522 1117</phone>
      <fax>+64 9 522 1127</fax>
      <email>aiservice@xtra.co.nz</email>
      <country>New Zealand</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Dr Michael Fredrickson</name>
      <address>Anaesthesia Institute
P O Box 109 199
Newmarket
Auckland 1149</address>
      <phone>+64 9 522 1117</phone>
      <fax>+64 9 522 1127</fax>
      <email>aiservice@xtra.co.nz</email>
      <country>New Zealand</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Margaret Watkin</name>
      <address>Anaesthesia Institute
P O Box 109 199
Newmarket
Auckland 1149</address>
      <phone>+64 9 522 1117</phone>
      <fax>+64 9 522 1127</fax>
      <email>aiservice@xtra.co.nz</email>
      <country>New Zealand</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Michael Fredrickson</name>
      <address>Anaesthesia Institute
P O Box 109 199
Newmarket
Auckland 1149</address>
      <phone>+6495221117</phone>
      <fax />
      <email>anaesthesiainstitute@yahoo.com</email>
      <country>New Zealand</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>